Patita Marta, Castro Rui, Libânio Diogo, Bastos Rui Pedro, Silva Rui, Dinis-Ribeiro Mário, Pimentel-Nunes Pedro
Gastroenterology Department, Hospital Garcia de Orta, Almada, Portugal.
Gastroenterology Department, Portuguese Oncology Institute of Porto, Porto, Portugal.
GE Port J Gastroenterol. 2020 Nov;27(6):383-390. doi: 10.1159/000507200. Epub 2020 May 13.
Self-expanding metal stents (SEMS) have been used for the palliative treatment of malignant gastrointestinal tract obstruction. However, restenosis or incomplete expansion of a first stent is a frequent complication, and the effectiveness of reintervention with placement of a second stent is still controversial.
To evaluate the clinical outcomes of covered SEMS (cSEMS) placement after dysfunction of uncovered SEMS (uSEMS) by the stent-in-stent technique.
We retrospectively studied a consecutive series of patients receiving palliative treatment for malignant gastrointestinal obstruction with cSEMS placement after uSEMS dysfunction in a tertiary center from January 2013 to August 2018. Technical and clinical success, time of patency, and adverse events were analyzed.
Twelve patients were included; their mean age was 60 ± 9 years. Eleven patients had gastric outlet obstruction, and 1 patient had compression of the transverse colon due to gastric neoplasia. In 5 cases, there was absence of early clinical success with uSEMS and stent dysfunction in 7 cases (median patency time: 81 days). There was 100% technical success and 91.7% clinical success after cSEMS placement. There were no adverse events nor need for reintervention. The median patency time after placement of both stents was 163 days (vs. 71 days with the initial stent).
cSEMS placement after uSEMS dysfunction is technically feasible and a clinically effective treatment for patients with recurrent malignant gastrointestinal obstruction, with good stent patency in the medium/long term. This approach seems to be safe and without increase in adverse effects.
自膨式金属支架(SEMS)已用于恶性胃肠道梗阻的姑息治疗。然而,首次置入支架后再狭窄或扩张不完全是常见并发症,再次置入第二个支架进行干预的有效性仍存在争议。
评估采用支架套入支架技术在裸金属支架(uSEMS)功能障碍后置入覆膜自膨式金属支架(cSEMS)的临床疗效。
我们回顾性研究了2013年1月至2018年8月在一家三级中心接受姑息治疗的一系列连续患者,这些患者在uSEMS功能障碍后接受了cSEMS置入以治疗恶性胃肠道梗阻。分析了技术成功率、临床成功率、通畅时间和不良事件。
纳入12例患者;平均年龄为60±9岁。11例患者有胃出口梗阻,1例患者因胃肿瘤导致横结肠受压。5例患者uSEMS早期临床未成功,7例出现支架功能障碍(中位通畅时间:81天)。cSEMS置入后技术成功率为100%,临床成功率为91.7%。无不良事件,也无需再次干预。两个支架置入后的中位通畅时间为163天(初始支架为71天)。
uSEMS功能障碍后置入cSEMS在技术上可行,是复发性恶性胃肠道梗阻患者的一种临床有效治疗方法,支架在中/长期具有良好的通畅性。这种方法似乎安全,且不会增加不良反应。